Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jul;39(7):1454–1457. doi: 10.1128/aac.39.7.1454

Susceptibilities of nontuberculosis mycobacterial species to amoxicillin-clavulanic acid alone and in combination with antimycobacterial agents.

L J Utrup 1, T D Moore 1, P Actor 1, J A Poupard 1
PMCID: PMC162761  PMID: 7492084

Abstract

Neither amoxicillin nor clavulanic acid used alone was active at the highest level tested, i.e., 256.0 micrograms/ml, in vitro against 24 isolates of Mycobacterium fortuitum, Mycobacterium kansasii, and Mycobacterium marinum. However, the MIC of an amoxicillin-clavulanic acid combination of 2:1 was < or = 8.0/4.0 micrograms/ml for 50 percent of the isolates tested, with all isolates being inhibited in the range of 4.0/2.0 to 32.0/16.0 micrograms/ml, respectively. Titration of amoxicillin-clavulanic acid with a fixed 2-micrograms/ml concentration of ethambutol resulted in synergistic activity against 3 of 9 isolates of M. fortuitum, 10 of 10 isolates of M. kansasii, and 5 of 5 isolates of M. marinum. This observation was confirmed in a checkerboard analysis in which fractional inhibitory concentrations were < or = 0.5 for 20 of the 24 isolates. Synergistic activity was observed against the other four isolates in one of two trials. On the other hand, titration of amoxicillin-clavulanic acid in the presence of either one or two fixed concentrations of isoniazid, rifampin, cycloserine, tetracycline, or amikacin failed to result in synergism.

Full Text

The Full Text of this article is available as a PDF (193.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amicosante G., Franceschini N., Segatore B., Oratore A., Fattorini L., Orefici G., Van Beeumen J., Frere J. M. Characterization of a beta-lactamase produced in Mycobacterium fortuitum D316. Biochem J. 1990 Nov 1;271(3):729–734. doi: 10.1042/bj2710729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bhattacharya C. P., Charkrabarty A. N., Dastidar S. G. Comparison of sensitivity of Mycobacterium spp. to combinations of clavulanic acid & penicillins with certain antitubercular agents. Indian J Med Res. 1988 Aug;88:118–123. [PubMed] [Google Scholar]
  3. Bloom B. R., Murray C. J. Tuberculosis: commentary on a reemergent killer. Science. 1992 Aug 21;257(5073):1055–1064. doi: 10.1126/science.257.5073.1055. [DOI] [PubMed] [Google Scholar]
  4. Casal M. J., Rodriguez F. C., Luna M. D., Benavente M. C. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium avium, Mycobacterium fortuitum, and Mycobacterium chelonae to ticarcillin in combination with clavulanic acid. Antimicrob Agents Chemother. 1987 Jan;31(1):132–133. doi: 10.1128/aac.31.1.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Casal M., Rodriguez F., Benavente M., Luna M. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to augmentin. Eur J Clin Microbiol. 1986 Aug;5(4):453–454. doi: 10.1007/BF02075706. [DOI] [PubMed] [Google Scholar]
  6. Cynamon M. H., Palmer G. S. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1983 Sep;24(3):429–431. doi: 10.1128/aac.24.3.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cynamon M. H., Palmer G. S. In vitro susceptibility of Mycobacterium fortuitum to amoxicillin or cephalothin in combination with clavulanic acid. Antimicrob Agents Chemother. 1983 Jun;23(6):935–937. doi: 10.1128/aac.23.6.935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Deng L., Mikusová K., Robuck K. G., Scherman M., Brennan P. J., McNeil M. R. Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Antimicrob Agents Chemother. 1995 Mar;39(3):694–701. doi: 10.1128/AAC.39.3.694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis. 1990 Oct;142(4):940–953. doi: 10.1164/ajrccm/142.4.940. [DOI] [PubMed] [Google Scholar]
  10. Fattorini L., Amicosante G., Fiorentino D., Franceschini N., Di Marzio L., Oratore A., Orefici G. Inhibitors and inactivators of beta-lactamase from Mycobacterium fortuitum. J Chemother. 1989 Oct;1(5):293–297. doi: 10.1080/1120009x.1989.11738911. [DOI] [PubMed] [Google Scholar]
  11. Fattorini L., Orefici G., Jin S. H., Scardaci G., Amicosante G., Franceschini N., Chopra I. Resistance to beta-lactams in Mycobacterium fortuitum. Antimicrob Agents Chemother. 1992 May;36(5):1068–1072. doi: 10.1128/aac.36.5.1068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Good R. C., Snider D. E., Jr Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis. 1982 Dec;146(6):829–833. doi: 10.1093/infdis/146.6.829. [DOI] [PubMed] [Google Scholar]
  13. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis. 1988 May;137(5):1217–1222. doi: 10.1164/ajrccm/137.5.1217. [DOI] [PubMed] [Google Scholar]
  14. Jarlier V., Gutmann L., Nikaido H. Interplay of cell wall barrier and beta-lactamase activity determines high resistance to beta-lactam antibiotics in Mycobacterium chelonae. Antimicrob Agents Chemother. 1991 Sep;35(9):1937–1939. doi: 10.1128/aac.35.9.1937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. KASIK J. E. THE NATURE OF MYCOBACTERIAL PENICILLINASE. Am Rev Respir Dis. 1965 Jan;91:117–119. doi: 10.1164/arrd.1965.91.1.117. [DOI] [PubMed] [Google Scholar]
  16. Mycobacterioses and the acquired immunodeficiency syndrome. Joint Position Paper of the American Thoracic Society and the Centers for Disease Control. Am Rev Respir Dis. 1987 Aug;136(2):492–496. doi: 10.1164/ajrccm/136.2.492. [DOI] [PubMed] [Google Scholar]
  17. Nadler J. P., Berger J., Nord J. A., Cofsky R., Saxena M. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest. 1991 Apr;99(4):1025–1026. doi: 10.1378/chest.99.4.1025. [DOI] [PubMed] [Google Scholar]
  18. Nash D. R., Wallace R. J., Jr, Steingrube V. A., Udou T., Steele L. C., Forrester G. D. Characterization of beta-lactamases in Mycobacterium fortuitum including a role in beta-lactam resistance and evidence of partial inducibility. Am Rev Respir Dis. 1986 Dec;134(6):1276–1282. doi: 10.1164/arrd.1986.134.5.1276. [DOI] [PubMed] [Google Scholar]
  19. O'Brien R. J., Geiter L. J., Snider D. E., Jr The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis. 1987 May;135(5):1007–1014. doi: 10.1164/arrd.1987.135.5.1007. [DOI] [PubMed] [Google Scholar]
  20. Silve G., Valero-Guillen P., Quemard A., Dupont M. A., Daffe M., Laneelle G. Ethambutol inhibition of glucose metabolism in mycobacteria: a possible target of the drug. Antimicrob Agents Chemother. 1993 Jul;37(7):1536–1538. doi: 10.1128/aac.37.7.1536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Swenson J. M., Wallace R. J., Jr, Silcox V. A., Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985 Dec;28(6):807–811. doi: 10.1128/aac.28.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Takayama K., Armstrong E. L., Kunugi K. A., Kilburn J. O. Inhibition by ethambutol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis. Antimicrob Agents Chemother. 1979 Aug;16(2):240–242. doi: 10.1128/aac.16.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Takayama K., Kilburn J. O. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother. 1989 Sep;33(9):1493–1499. doi: 10.1128/aac.33.9.1493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wallace R. J., Jr, Swenson J. M., Silcox V. A., Good R. C., Tschen J. A., Stone M. S. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis. 1983 Jul-Aug;5(4):657–679. doi: 10.1093/clinids/5.4.657. [DOI] [PubMed] [Google Scholar]
  25. Wong C. S., Palmer G. S., Cynamon M. H. In-vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium kansasii to amoxycillin and ticarcillin in combination with clavulanic acid. J Antimicrob Chemother. 1988 Dec;22(6):863–866. doi: 10.1093/jac/22.6.863. [DOI] [PubMed] [Google Scholar]
  26. Young L. S. The Garrod Lecture. Mycobacterial diseases in the 1990s. J Antimicrob Chemother. 1993 Aug;32(2):179–194. doi: 10.1093/jac/32.2.179. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES